Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.
177Lu-PSMA-617 radioligand therapy
biomarkers
mCRPC
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
10
2021
accepted:
02
02
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice.
Identifiants
pubmed: 35273651
doi: 10.1177/17588359221081922
pii: 10.1177_17588359221081922
pmc: PMC8902011
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359221081922Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
J Nucl Med. 2017 Feb;58(2):312-319
pubmed: 27587707
Oncotarget. 2017 Oct 7;8(61):103108-103116
pubmed: 29262549
J Nucl Med. 2021 Aug 12;:
pubmed: 34385339
Lancet Oncol. 2021 Aug;22(8):1115-1125
pubmed: 34246328
Prostate. 2020 Jan;80(1):74-82
pubmed: 31614001
Br J Radiol. 2019 Dec;92(1104):20190380
pubmed: 31600089
Curr Med Chem. 2012;19(6):856-70
pubmed: 22214450
PLoS One. 2020 Jan 27;15(1):e0226219
pubmed: 31986176
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1075-1085
pubmed: 34494131
Prostate. 2020 Jan;80(1):17-27
pubmed: 31579967
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1200-1210
pubmed: 32970216
J Nucl Med. 2021 Jul 29;:
pubmed: 34326127
J Nucl Med. 2019 Jul;60(7):955-962
pubmed: 30683770
J Nucl Med. 2018 Sep;59(9):1406-1411
pubmed: 29371407
Anticancer Res. 2018 Nov;38(11):6029-6039
pubmed: 30396917
J Nucl Med. 2020 Oct;61(10):1476-1483
pubmed: 32111687
J Nucl Med. 2021 Mar 31;:
pubmed: 33789932
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562686
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122
pubmed: 32383093
J Nucl Med. 2018 Jun;59(6):929-933
pubmed: 29419479
Eur Urol Open Sci. 2021 Jun 30;30:63-66
pubmed: 34337549
Lancet. 2014 Dec 6;384(9959):2027-35
pubmed: 25108889
Theranostics. 2020 Jun 18;10(17):7645-7655
pubmed: 32685010
J Natl Cancer Inst. 2012 Jan 18;104(2):125-32
pubmed: 22228146
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Int J Mol Sci. 2020 Nov 28;21(23):
pubmed: 33260535
Cancers (Basel). 2020 Apr 26;12(5):
pubmed: 32357427
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4067-4076
pubmed: 34031719
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):136-146
pubmed: 31492993
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Curr Opin Urol. 2020 Sep;30(5):635-640
pubmed: 32732621
Biomolecules. 2021 Jul 26;11(8):
pubmed: 34439768
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670
pubmed: 28624848
Theranostics. 2019 Jul 9;9(17):4841-4848
pubmed: 31410185
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2322-2327
pubmed: 32140802
PLoS One. 2015 Jul 28;10(7):e0134134
pubmed: 26218594
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Nucl Med Commun. 2016 Nov;37(11):1169-79
pubmed: 27333090
Clin Nucl Med. 2020 Dec;45(12):935-942
pubmed: 32956129
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072
pubmed: 30569186
J Steroid Biochem Mol Biol. 2013 Nov;138:248-56
pubmed: 23792785
Int J Urol. 2017 Sep;24(9):668-673
pubmed: 28556293
Cancers (Basel). 2021 Aug 02;13(15):
pubmed: 34359805
J Nucl Med. 2020 May;61(5):689-695
pubmed: 31653712
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
Theranostics. 2020 Jun 19;10(17):7812-7820
pubmed: 32685021
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1650-1657
pubmed: 33128131
Clin Genitourin Cancer. 2019 Feb;17(1):15-22
pubmed: 30425003